EGFR and neoplasm: These results indicated that the observed tumor progression was not due to one of the known mechanisms of acquired crizotinib resistance, i.e. loss of ALK rearrangement, amplification of ALK fusion gene, or secondary ALK mutations [9,13,15], but was most likely due to the emergence of concurrent EGFR and KRAS mutations.